CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
TIMEUP›
Library
TIMEUP

TIMEUP

TIMEUP develops diagnostic devices for continuous detection of urinary pathogens in patients with urinary catheters.

Operating headquarters
Coimbra, PT🇵🇹
Loading
Overview
Compare
Fundraising
Employees
Library

TIMEUP - Library

timeuphealth.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Press

2 pages
  1. TIMEUP is one of the Women TechEU winners/timeup/timeup-is-one-of-the-women-techeu-winners

    Marta Santos, CEO of TIMEUP, Lda., was one of the woman founders awarded by Women TechEU, a European Union initiative aimed at supporting women-led technology startups across Europe.This award recognizes the TIMEUP, Lda. female team for its innovation in the health technology sector. In addition to funding, the program provided access to mentorship and a

  2. TIMEUP, Lda. Secures Approval from PT2030 for a €1M Demonstrator Project/timeup/timeup-lda-secures-approval-from-pt2030-for-a-e1m-demonstrator-project

    TIMEUP, Lda., a spin-off of the University of Coimbra (UC) and the Polytechnic of Coimbra (IPC), has obtained approval for the DiUp Project under the SIID Programme 2025 – “Projetos Demonstradores em Copromoção”, with a total funding of 1 million euros. TIMEUP, Lda., as the project Promoter, is joined by the University of Coimbra, the

About

1 page
  1. About us/timeup/about-us

    TimeUp Team Linkedin Linkedin Linkedin Linkedin Linkedin TEAM MEMBERS BIOGRAPHY Susana Alarico Graduated in Biology from the University of Aveiro in 1999. She obtained a master’s degree in Cellular Biology (2003) and a PhD in Biology, specialty Microbiology (2009) both at the University of Coimbra. She has been carrying out research for 24 years in

Homepage

1 page
  1. TimeUp/timeup/timeup

    TimeUp is a Diagnostic Device for the detection of uropathogens in urinary catheters, before the progression to Urinary Tract Infections. Menu The Problem Gold Standards Our Solutions Achievements Problem Catheters-Associated Urinary Tract Infections (CAUTIs) 70 to 80% of Urinary Tract Infections are in catheterized patientsRisk of developing CAUTI increases up to 10% for each day